What is the typical dosage of budesonide for asthma, allergic rhinitis, Crohn's disease, and ulcerative colitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Budesonide Dosage Recommendations by Condition

For asthma, allergic rhinitis, Crohn's disease, and ulcerative colitis, budesonide dosages vary by condition, with 9 mg once daily for ulcerative colitis, 9 mg once daily for Crohn's disease, 200-800 mcg twice daily for asthma in adults, and 400 mcg twice daily for allergic rhinitis.

Asthma Dosing

Adults

  • For mild to moderate asthma in adults, the recommended dose is 200-800 mcg twice daily via metered dose inhaler, depending on severity 1
  • Once-daily dosing (800 mcg) may be as effective as twice-daily dosing (400 mcg twice daily) in some patients with mild persistent asthma 2, 3
  • However, for long-term maintenance of moderate asthma, twice-daily dosing provides better symptom control than once-daily dosing 4

Children

  • For children 5-11 years: 200-400 mcg twice daily via metered dose inhaler 1
  • For children under 4 years: 0.25-0.5 mg (250-500 mcg) twice daily via nebulizer 1, 5
  • The FDA-approved budesonide inhalation suspension for children under 4 years should be administered twice daily 6
  • Low daily dose: 0.25-0.5 mg total daily dose (0.125-0.25 mg twice daily) 6
  • Medium daily dose: 0.5-1.0 mg total daily dose (0.25-0.5 mg twice daily) 6
  • High daily dose: >1.0-2.0 mg total daily dose (>0.5-1.0 mg twice daily) 6

Crohn's Disease Dosing

  • For mild to moderate ileal and/or right colonic Crohn's disease, oral budesonide should be started at 9 mg/day as first-line therapy to induce remission 7
  • Patients should be evaluated for response between 4 and 8 weeks to determine if therapy modification is needed 7
  • Once-daily dosing (9 mg OD) is as effective as three-times daily dosing (3 mg TID) for active Crohn's disease 8
  • Budesonide is not recommended for maintenance of remission in Crohn's disease 7

Ulcerative Colitis Dosing

  • For induction of remission in adults with active, mild to moderate ulcerative colitis, the recommended dosage is 9 mg taken orally once daily in the morning for up to 8 weeks 9
  • Budesonide extended-release tablets should be swallowed whole and not chewed, crushed, or broken 9
  • In patients with mild-moderate ulcerative colitis, standard-dose oral mesalamine or diazo-bonded 5-ASA is suggested rather than budesonide MMX for induction of remission 7

Allergic Rhinitis Dosing

  • For allergic rhinitis in adults, the typical dose is 400 mcg twice daily via nasal spray 1
  • Rinsing the mouth after use is recommended to prevent oral candidiasis 1

Administration Considerations

  • For asthma treatment via nebulizer, use a jet nebulizer with a standard flow rate compressor 6
  • For young children, use a face mask that fits snugly over the nose and mouth 6
  • Wash the face after each treatment to prevent local side effects such as oral candidiasis 6
  • For oral budesonide (Crohn's disease and ulcerative colitis), avoid grapefruit juice which inhibits CYP3A4 9
  • If using with CYP3A4 inhibitors, monitor for increased signs of hypercorticism 9

Monitoring and Follow-up

  • For asthma, assess response to budesonide between 2 to 8 days, although maximum benefit may not be achieved for 4 to 6 weeks 5
  • For Crohn's disease, evaluate response between 4 and 8 weeks 7
  • For ulcerative colitis, treatment duration is up to 8 weeks 9
  • Monitor for local side effects such as oral candidiasis and dysphonia in patients using inhaled formulations 1
  • In children, monitor growth as suppression of growth velocity has been observed with inhaled corticosteroid use 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.